[Hematological disorders and hypereosinophilias].

No abstract is available for this paper.

• Publication year

  2009

• Venue

  La Revue de medecine interne

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.revmed.2008.10.019PMID 19201511
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.

  2008cited by this paper
• Time course of eosinophilic myocarditis visualized by CMR

  2008cited by this paper
• Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

  2008cited by this paper
• Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease.

  2008cited by this paper
• A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1‐PDGFRA‐expressing patients

  2008cited by this paper
• Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms

  2008cited by this paper
• 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course.

  2007cited by this paper
• Eosinophilia: A study of 100 hospitalized patients.

  2007cited by this paper
• Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

  2007cited by this paper
• The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study

  2007cited by this paper
• Two novel imatinib‐responsive PDGFRA fusion genes in chronic eosinophilic leukaemia

  2007cited by this paper
• Lymphocytic variant hypereosinophilic syndromes.

  2007cited by this paper
• Interferon α induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation

  2007cited by this paper
• Diagnosis and treatment of hypereosinophilic syndromes

  2007cited by this paper
• Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

  2007cited by this paper
• The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

  2006cited by this paper
• Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report.

  2006cited by this paper
• A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia.

  2006cited by this paper
• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

  2006cited by this paper
• The eosinophil.

  2006influential reference
• Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome

  2006cited by this paper
• FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature.

  2006cited by this paper
• Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene

  2006cited by this paper
• Sorafenib is a potent inhibitor of FIP 1 L 1-PDGFR and the imatinib-resistant FIP 1 L 1-PDGFR T 674 I mutant

  2006cited by this paper
• Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

  2006cited by this paper
• Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

  2006cited by this paper
• Congestive heart failure is a rare event in patients receiving imatinib therapy.

  2006cited by this paper
• Interferon Treatment for Hypereosinophilic Syndromes and Systemic Mastocytosis

  2005cited by this paper
• [Cardiac manifestations of idiopathic hypereosinophilic syndrome].

  2005cited by this paper
• Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics

  2005cited by this paper
• Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

  2005cited by this paper
• Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.

  2004cited by this paper
• Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

  2004cited by this paper
• Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.

  2004cited by this paper
• Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis

  2004cited by this paper
• Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias

  2004cited by this paper
• Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

  2003cited by this paper
• Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.

  2003cited by this paper
• Eosinophilia and diseases: clinical revision of 1862 cases.

  2003cited by this paper
• PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

  2003cited by this paper
• Herb-drug interactions: survey of leading pharmaceutical/herbal companies.

  2003cited by this paper
• Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

  2003cited by this paper
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

  2003cited by this paper
• High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome.

  2002cited by this paper
• Myeloproliferative Disorders with Translocations of Chromosome 5q31–35: Role of the Platelet-Derived Growth Factor Receptor Beta

  2002cited by this paper
• Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta.

  2002cited by this paper
• The 8p11 Myeloproliferative Syndrome: A Distinct Clinical Entity Caused by Constitutive Activation of FGFR1

  2002cited by this paper
• Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

  2002cited by this paper
• Treatment of hypereosinophilic syndrome with imatinib mesilate.

  2002cited by this paper
• The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

  2002cited by this paper
• RESPONSE TO IMATINIB MESYLATE IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISEASES WITH REARRANGEMENTS OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA

  2002cited by this paper
• Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia‐associated diseases

  2002cited by this paper
• Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome

  2000cited by this paper
• Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia.

  2000cited by this paper
• Clonal Th 2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome

  2000cited by this paper
• Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder.

  2000cited by this paper
• Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia.

  1999cited by this paper
• Eosinophilia.

  1998cited by this paper
• The idiopathic hypereosinophilic syndrome.

  1994cited by this paper
• Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.

  1994cited by this paper
• Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome.

  1994influential reference
• [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases].

  1993cited by this paper
• Therapy of the hypereosinophilic syndrome.

  1978cited by this paper

• Three cases of feline hypereosinophilic syndrome treated with imatinib mesilate

  2014cites this paper
• [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].

  2011cites this paper
• [Endomyocardial disease as the first manifestation of hypereosinophilic syndrome].

  2010cites this paper
• [Efficiency of imatinib in polyserositis revealing a FIP1L1-PDGFRA-negative hypereosinophilic syndrome].

  2010cites this paper